Industry Briefs: November 12, 2012
A roundup of additional company and people news from pharmaceutical and biopharmaceutical companies, their suppliers, and contract-service providers.
Company News
AstraZeneca and Foundation Medicine have entered into a collaboration to identify alterations found in cancer-related tumor genes that may predict a person’s response or resistance to targeted medicines.
Boehringer Ingelheim and BaroFold have entered into a nonexclusive technology and commercial license option agreement. Boehringer Ingelheim will acquire a laboratory-scale reactor of BaroFold’s pressure-enabled manufacturing technology that can also be qualified for GMP use. The technology will be installed at Boehringer Ingelheim’s microbial facility in Vienna, Austria, and will be available for development of biopharmaceutical production processes.
Cytovance Biologics and Selexys Pharmaceuticals have formed a biomanufacturing agreement for Phase II Production of the monoclonal antibody SelG1.
GP Pharm has agreed to manufacture Pharmalink’s Busulipo, which is under development to provide a conditioning agent for use before hematopoietic stem-cell transplantation, or bone-marrow transplantation.
Immune Pharmaceuticals and EpiCept have entered into a definitive merger agreement. The transaction is expected to close during the first quarter of 2013.
Merck & Co. and the Regenstrief Institute have signed a five-year agreement to collaborate on a range of projects that will use clinical data to inform personalized delivery of healthcare.
MonoSol Rx and BiondVax Pharmaceuticals have entered an agreement to develop oral delivery for BiondVax’s universal flu vaccine, M-001.
Mylan and Famy Care have entered into a settlement agreement with Janssen Pharmaceuticals that will resolve patent litigation related to norgestimate/ethinyl estradiol tablets 0.180 mg/0.025 mg, 0.215 mg/0.025 mg, and 0.250 mg/0.025 mg. Norgestimate/ethinyl estradiol tablets are the generic version of Janssen’s Ortho Tri-Cyclen Lo Tablets, which are indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception.
Pfizer has concluded its partnership with Auxilium Pharmaceuticals for Xiapex (collagenase clostridium histolyticum) in the European Union.
Sigma-Aldrich has acquired Research Organics.
Synthetic Biologics has agreed to acquire Prev AbR’s clinical-stage C. difficile infectious-disease program.
People News
Bosch Packaging Technology has announced several leadership changes. Uwe Harbauer has been appointed senior vice-president of the company’s pharmaceutical business unit, Wolfgang Szczerba is retiring after 34 years of service at Bosch, and Walter Häcki has been appointed senior vice-president of packaging services.
Tyson Popp, vice-president, global sourcing and Americas supply chain, West Pharmaceutical Services, has been elected president of the Drug, Chemical & Associated Technologies Association (DCAT) by the DCAT membership. He assumed the office on Nov. 1, 2012. Also elected to serve as officers were Lyra Myers, associate director and value creation agent, Genentech; George Svokos, senior vice president, product and portfolio management, Teva Pharmaceuticals USA; and Folker Ruchatz, vice-president, global business management custom synthesis, BASF.
Novartis has announced that Marjorie Yang has decided not to seek re-election to the Novartis board of directors.
Newsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.
